Management of Ankylosing Spondylitis

Overarching Principles

• The European League Against Rheumatism recommends that ankylosing spondylitis is a potentially severe disease with diverse manifestations, requiring multidisciplinary treatment coordinated by the rheumatologist 1, 2
• The primary goal is to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention of structural damage, and preservation of function, as suggested by the European League Against Rheumatism 3, 4
• Treatment should be based on a shared decision between the patient and rheumatologist, according to the European League Against Rheumatism 2, 5

Treatment Approach

Individualized Treatment Considerations

• Treatment should be tailored according to current disease manifestations, level of current symptoms, and general clinical status, as recommended by the European League Against Rheumatism 1, 4
• The European League Against Rheumatism suggests considering age, gender, comorbidities, concomitant medications, and psychosocial factors when tailoring treatment 1, 5

Non-Pharmacological Treatment

• The European League Against Rheumatism recommends patient education and regular exercise as the cornerstone of non-pharmacological treatment 1, 2
• Physical therapy with supervised exercises is more effective than home exercises alone, according to the European League Against Rheumatism 1, 2

Pharmacological Treatment

First-Line: NSAIDs

• The European League Against Rheumatism recommends NSAIDs, including COX-2 inhibitors, as first-line drug treatment for pain and stiffness 1, 4
• Continuous NSAID treatment is preferred for patients with persistently active, symptomatic disease, as suggested by the European League Against Rheumatism 1, 4

Biological Therapy: TNF Inhibitors

• The European League Against Rheumatism recommends anti-TNF therapy for patients with persistently high disease activity despite conventional treatments 1, 6
• There is no evidence supporting mandatory use of DMARDs before or with anti-TNF therapy in axial disease, according to the European League Against Rheumatism 1, 6

Surgical Interventions

• The European League Against Rheumatism suggests considering total hip arthroplasty in patients with refractory pain/disability and radiographic evidence of structural damage 1
• Spinal corrective osteotomy may be considered for severe disabling deformity, as recommended by the European League Against Rheumatism 1

Management of Extra-articular Manifestations

• Extra-articular manifestations should be managed in collaboration with respective specialists, according to the European League Against Rheumatism 1, 5
• Rheumatologists should monitor for increased risk of cardiovascular disease and osteoporosis, as suggested by the European League Against Rheumatism 1, 5

Common Pitfalls to Avoid

• Overlooking the importance of physical therapy and exercise is a common pitfall, according to the European League Against Rheumatism 1, 2
• Inappropriate use of systemic corticosteroids for axial disease is another common pitfall, as recommended by the European League Against Rheumatism 1, 7
• Failing to consider TNF inhibitors in patients with persistently active disease despite NSAIDs is a common pitfall, according to the European League Against Rheumatism 6

Etoricoxib in Ankylosing Spondylitis

Evidence for Efficacy

• The ASAS/EULAR guidelines establish NSAIDs, including coxibs, as first-line pharmacological treatment for AS patients with pain and stiffness, with Level Ib evidence supporting the use of etoricoxib as a COX-2 selective NSAID 8, 9, 10, 11

Dosing Algorithm

• The ASAS/EULAR guidelines recommend continuous daily dosing rather than on-demand use for patients with persistently active, symptomatic disease 10

Cardiovascular and Gastrointestinal Risk Assessment

• Coxibs, including etoricoxib, have a lower risk of serious GI events than traditional NSAIDs, though GI symptoms like dyspepsia and diarrhea remain common 8, 9
• The ASAS/EULAR guidelines recommend co-prescribing a proton pump inhibitor for gastroprotection in patients with GI risk factors 10, 11

Comparative Safety Profile

• Cardiovascular toxicity appears to be a class effect of coxibs, with emerging evidence suggesting traditional NSAIDs may share some of this risk 8, 9, 11

Effect on Structural Disease

• Continuous celecoxib treatment has shown possible disease-modifying effects by retarding radiographic progression at 2 years in one RCT, in contrast to etoricoxib which has minimal effect on MRI-detected inflammatory lesions in AS 10, 11